Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats.

Shao Q; Meng L; Lee S; Tse G; Gong M; Zhang Z; Zhao J; Zhao Y; Li G; Liu T

doi:10.1186/s12933-019-0964-4

Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats.

Identifier:nobleid.org/w1/20260526/9FDDF0DC

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/9FDDF0DC.svg?ark=w1%2F20260526%2F9FDDF0DC)](https://nobleid.org/work/w1/20260526/9FDDF0DC)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats.

Identifier:nobleid.org/w1/20260526/9FDDF0DC

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/9FDDF0DC.svg?ark=w1%2F20260526%2F9FDDF0DC)](https://nobleid.org/work/w1/20260526/9FDDF0DC)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work